Advisory
Ambrosia operates in the middle. Senior attention throughout. Cross-border execution capability where boutiques can’t operate and bulge brackets won’t engage. Deal intelligence and structuring depth that lets us run conversations on the same footing as the principals.
Transaction Scope
Engagement Tiers
Companies getting ready to go to market.
Clinical-stage companies, typically Series A or early Series B, with one to two lead assets. 10 to 40 headcount. Often pre-data or approaching a meaningful readout. The work is positioning, not process — making sure the asset story, the competitive frame, and the deal structure are right before any counterparty sees them.
Companies with a transaction in motion.
Late Series B or Series C, actively running a licensing, partnering, or co-development process. The asset is real, the counterparties are identifiable, and the question is how to structure and close. We design the outreach, manage the process, and sit across the table in every negotiation.
Full execution mandates for material transactions.
Post-Series C and commercial-stage companies running competitive sale processes, mid-pharma acquirers facing patent cliffs, and cross-border deals that require regulatory, IP, and structural fluency no single jurisdiction can provide.
Engagement Architecture
We’ll meet you at peer level — anywhere in the world.